Omacor for Perimenopausal Depression
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00517972|
Recruitment Status : Withdrawn
First Posted : August 17, 2007
Last Update Posted : March 29, 2012
|Condition or disease||Intervention/treatment||Phase|
|Depression||Drug: Omacor (omega-3-acid ethyl esters)||Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Omacor for Perimenopausal Depression|
- Reduction of the initial HAM-D score by 50% or more at week 8 of the trial.
- Reduction of the HAM-D score to less than 7 at week 8.
- Clinical Global Impression change in score achievement to "very much improved" or "much improved" at week 8.
- Decrease in the Greene Climacteric Scale by 50%.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00517972
|United States, Arizona|
|Women's Mental Health Program; University of Arizona|
|Tucson, Arizona, United States, 85724|
|Principal Investigator:||Marlene P Freeman, M.D.||University of Arizona|